US Judge Blocks WuXi AppTec 'Chinese Military' Label

US Judge Blocks WuXi AppTec 'Chinese Military' Label

A US federal judge has temporarily blocked the Pentagon from designating WuXi AppTec, one of China's largest pharmaceutical research and manufacturing service providers, as a "Chinese military company," ruling that defence officials repeatedly misread the evidence used to justify the decision. The preliminary injunction, issued by US District Chief Judge James Boasberg in Washington on Friday, hands the Shanghai-headquartered company an early legal victory and delivers a pointed rebuke to the expanding use of national-security restrictions against major Chinese commercial companies.

Tags: WuXi AppTec, Pentagon, Section 1260H, Chinese military company, BIOSECURE Act, US-China relations, biotech decoupling, CDMO, James Boasberg, preliminary injunction, pharmaceutical supply chain, national security

What the Court Ordered

Boasberg granted WuXi a preliminary injunction barring the Department of Defence from enforcing or otherwise giving effect to the designation while the company's lawsuit proceeds. "A scarlet letter sends a clear message: keep away," the judge wrote in a 35-page opinion, pointing to customers and suppliers that had cancelled contracts, ended long-standing relationships, or moved business to WuXi's competitors after the designation appeared on the Pentagon's Section 1260H list in June.

The ruling does not permanently remove WuXi from the list, nor does it prevent the department from designating the company again using evidence and reasoning that satisfy the law. It also does not affect Alibaba, Baidu, BYD or other Chinese companies on the list — though analysts say Boasberg's rejection of unsupported evidence could strengthen similar legal challenges based on indirect state or military affiliations. Alibaba, which owns the South China Morning Post, has separately sued the Pentagon over its own addition to the list.

The Evidence the Judge Called 'Flat-Out Wrong'

WuXi was added to the list in June after the Pentagon alleged it was indirectly owned by China's State-owned Assets Supervision and Administration Commission, or Sasac, and indirectly affiliated with the State Administration of Science, Technology and Industry for National Defence and the People's Liberation Army. Boasberg found that each of those three rationales was likely deficient under the Administrative Procedure Act, which allows courts to set aside government actions found to be arbitrary or capricious.

The ownership finding rested largely on an investment in WuXi by a fund connected to the Aviation Industry Corporation of China, a state-owned aerospace and defence conglomerate overseen by Sasac. According to the judge, defence officials confused the percentage of the fund's assets invested in WuXi with the percentage of WuXi owned by the fund. A source cited by the Pentagon said WuXi shares represented 5.32 per cent of the fund's net asset value; the department interpreted that to mean the fund owned 5.32 per cent of WuXi. "This is flat-out wrong," Boasberg wrote. "If a household puts 5 per cent of its modest savings into a blue-chip stock, that does not mean it owns 5 per cent of the company."

WuXi told the court the fund's actual investment was worth around US$200,000, representing about 0.001 per cent of the company's equity. Boasberg said he did not need to accept those figures to conclude the Pentagon had mischaracterised its own sources. "These errors do not inspire confidence in the fastidiousness of the agency's decision-making process," he wrote.

Affiliation Claims Built on Remote Laboratory Roles

The court found similar problems with the Pentagon's claims that WuXi was affiliated with China's defence-industry regulator and the PLA. Those conclusions were based on records of pharmaceutical studies involving hospitals affiliated with five universities supervised by the defence regulator, plus one study involving the PLA General Hospital. But the underlying records identified WuXi or its subsidiaries only as third-party laboratories hired to process samples; other pharmaceutical companies had applied for government approval and selected the hospitals where the studies would take place.

The judge said the records did not establish the "close formal or informal association" the statute requires. Highlighting the breadth of the government's reasoning, he noted the same collection of records listed the University of Michigan as an applicant for a study conducted at a hospital affiliated with Peking University. "If WuXi's more remote role suffices to establish a close association with SASTIND, the report's logic would make a member of the Big Ten a Chinese military company," he wrote. Boasberg stressed that courts owe considerable deference to government decisions involving national security, but said that deference "cannot compensate for evidence that did not support the Pentagon's stated conclusions."

Commercial Damage and the Biosecure Act Stakes

The judge also found WuXi was suffering irreparable commercial harm. The company operates six facilities and employs about 450 people in the United States, serving more than 1,000 US customers that accounted for roughly 70 per cent of its US$6.7 billion in global revenue last year, according to the opinion. Since the designation, customers have suspended work, cancelled projects or begun transferring programmes to other suppliers. Because pharmaceutical development programmes can last for years and switching manufacturers may require new regulatory submissions and validation work, Boasberg found that customers moving to competitors were unlikely to return even if WuXi ultimately prevailed.

The designation also carries consequences under the Biosecure Act, which requires the White House budget office to publish an initial list of "biotechnology companies of concern" by December. Being placed on the Section 1260H list is necessary, although not sufficient by itself, for inclusion on that list. Companies ultimately covered could be excluded from federally funded contracts and supply chains — a risk that has pushed US drugmakers to map their exposure to Chinese contract development and manufacturing organisations, the dominant players in the global CDMO market.

What the Ruling Means for Asia-Pacific Pharma

For Japan and the wider Asia-Pacific pharmaceutical industry, the case is a live demonstration of how Washington's decoupling agenda can reach into the region's most integrated supply chains. Japanese drugmakers, like their American counterparts, rely on Chinese CDMOs for clinical development, manufacturing and scale-up; WuXi AppTec is the largest of those providers, and the industry's Asia-Pacific CDMO market is projected to roughly double from about US$83 billion in 2025 to more than US$160 billion by 2035. A designation that sticks would not only disrupt US drug development but could force a region-wide reassessment of where the next generation of biologic and small-molecule drugs gets manufactured.

The ruling does not end that pressure — it pauses one company's listing while the legal questions are resolved. But it establishes a judicial checkpoint on the evidentiary standards Washington must meet before it labels a company a military affiliate, and it signals that courts will scrutinise the factual basis of a list that carries real commercial consequences across the Asia-Pacific.

What to Watch For

The Pentagon declined to address the ruling or say whether it plans to appeal, citing its policy of not commenting on ongoing litigation. Boasberg rejected the government's request to stay the injunction during an appeal, saying it had not identified any immediate and irreparable harm from the temporary suspension. WuXi AppTec did not immediately respond to a request for comment.

Three threads will determine where this goes: whether the Department of Defence appeals and how the appeals court treats the factual findings; whether the December Biosecure Act list includes WuXi despite the injunction; and whether Alibaba and other listed companies now press their own challenges with the judge's 35-page opinion as a template. For pharmaceutical executives from Tokyo to Boston, the case is also a reminder that in the current US-China climate, a company's most important compliance document may be the evidence file behind its government designations — and that getting the math wrong in Washington can now be challenged, successfully, in court.

By Kenji Tanaka, Staff Writer

This article was produced with AI-assisted research and editorial support. Reporting is based on sources cited in the article.